跳转至内容
Merck

SML1884

Sigma-Aldrich

Mitoglitazone

≥98% (HPLC)

别名:

5-[[4-[2-(5-ethyl-2-pyridinyl)-2-oxoethoxy]phenyl]methyl]-2,4-thiazolidinedione, MSDC-0160

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H18N2O4S
分子量:
370.42
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 20 mg/mL, clear

儲存溫度

−20°C

SMILES 字串

CCC1=CN=C(C(COC2=CC=C(CC3SC(NC3=O)=O)C=C2)=O)C=C1

InChI

1S/C19H18N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,17H,2,9,11H2,1H3,(H,21,23,24)

InChI 密鑰

IRNJSRAGRIZIHD-UHFFFAOYSA-N

生化/生理作用

MSDC-0160 is an mTOT (mitochondrial target of thiazolidinediones) modulator that targets the mitochondrial pyruvate carrier (MPC), which is a key controller of cellular metabolism. MSDC-0160 is reported to enhance the cells′ ability to handle potentially harmful proteins, which leads to reduced inflammation and less nerve cell death. It has already been in clinical trials for diabetes and Alzheimer′s disease and clinical trials for Parkinson′s Disease are planned.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Nidhi Rohatgi et al.
PloS one, 8(5), e62012-e62012 (2013-05-08)
Major bottlenecks in the expansion of human β-cell mass are limited proliferation, loss of β-cell phenotype, and increased apoptosis. In our previous studies, activation of Wnt and mTOR signaling significantly enhanced human β-cell proliferation. However, isolated human islets displayed insulin
Anamitra Ghosh et al.
Science translational medicine, 8(368), 368ra174-368ra174 (2016-12-09)
Mitochondrial and autophagic dysfunction as well as neuroinflammation are involved in the pathophysiology of Parkinson's disease (PD). We hypothesized that targeting the mitochondrial pyruvate carrier (MPC), a key controller of cellular metabolism that influences mTOR (mammalian target of rapamycin) activation
Raj C Shah et al.
Current Alzheimer research, 11(6), 564-573 (2014-06-17)
Alzheimer's disease (AD) is associated with insulin resistance and specific regional declines in cerebral metabolism. The effects of a novel mTOT modulating insulin sensitizer (MSDC-0160) were explored in non-diabetic patients with mild AD to determine whether treatment would impact glucose

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门